
I'M JUST DOING MY JOB

See Film presentation at: https://odysee.com/@PandemicParallaxView:6/LetTheScienceSpeak-SLKW-100423:f

See Also: MEMO to Senator Ron Johnson RE: Evidence of Covid-19 Regulatory Failures, Criminal Wrongdoing and Attempts to Avoid Liability by Senior Executive Service Officials in Multiple Federal Agencies https://ratical.org/PandemicParallaxView/MEMOsenRJUSCcrime-122222.html

Weaponized "Healthcare" for Global Population Control and Enslavement

Sasha Latypova Sashalatypova.substack.com





Summary of All Evidence => Intent to Harm

- Toxic by Design: Mechanisms of injury designed into C-19 injections & drugs, nonvalidated diagnostics + fear rituals (masking and distancing)
- No Safety: hospital murder protocols (false PCR+remdesivir+midazolam+vent) driving "covid mortality", ~17 million deaths by "covid vaccines" globally
- No Efficacy: vax <u>negative</u> efficacy, kidney failure by remdesivir
- **Bad Manufacturing:** Highly variable production, non-compliant with cGMP, no enforcement of cGMP by any agency
- Malignant Policy Worldwide: Government lies, cover-up, gaslighting of the injured, prosecution of dissent and whistleblowers, collusion with media, perverse financing of the above =><u>intent to harm</u>

Product does not conform to labels (worldwide vial testing)*


- RNA non-conforming to label
- PlasmidDNA + SV40!
- Toxic metals of unknown origin or purpose:
 - Caesium, potassium, calcium, barium, cobalt, iron, chromium, titanium, cerium, gadolinium, aluminum, silicon, sulfur, thulium, antimony.
- Hydrogel (DARPA hydrogel?) + Graphene oxide?
- Micro- and macro-objects/structures:
 - "blobs", particles, crystals, square shapes, fibers, ribbons, etc.






*David Hughes, PhD <u>https://ijvtpr.com/index.php/IJVTPR/article/view/52</u>

Independent Illumina sequencing



What was disclosed to the EMA



Next Generation Bioweapons: Genetic Engineering and BW

Next Generation Bioweapons: Genetic Engineering and BW

Michael J. Ainscough



14

US Air Force Counterproliferation Center Future Warfare Series No. 14 the contributions of scientists to problems of national security and public benefit." Their meeting concentrated on the near-term future threat of biological warfare, specifically on genetically engineered pathogens and weapons.

The JASON Group that met in 1997 grouped potential genetically engineered pathogens into six broad groups of potential futuristic threats.⁸⁵

- Binary biological weapons
- Designer genes
- *Gene therapy as a weapon*
- Stealth viruses
- Host-swapping diseases
- Designer diseases

3) <u>**Gene Therapy as a Weapon**</u>:⁹⁶ Gene therapy will revolutionize the treatment of human genetic diseases. The goal is to effect a permanent change in the genetic composition of a person by repairing or replacing a faulty gene. Genes have already been spliced into bacteria to produce "human" insulin in large quantities.⁹⁷ The eventual goal is to splice a gene that codes for the production of insulin into human pancreatic tissue to cure diabetes. Similar research is progressing on adding in the missing gene to prevent the symptoms of cystic fibrosis. However, the same technology could be subverted to insert pathogenic genes.

Case Details

VAERS ID: 2414702 (history)		Vaccinated:	2022-08-12	
Form:	Version 2.0	Onset:	2022-08-13	
Age:	10.0	Days after vacci	nation: 1	
Sex:	Male	Submitted:	000-00-00	
Location:	Unknown	Entered:	2022-08-18	

Vaccination / Manufacturer	Lot / Dose	Site / Route
COVID19: COVID19 (COVID19 (PFIZER-BIONTECH)) / PFIZER/BIONTECH	FL8095 / 1	UN / IM

Administered by: Private Purchased by: ?

D

Symptoms: Bradycardia, Cardiac arrest, Cardiac valve disease, Culture, Death, Echocardiogram abnormal, Ejection fraction decreased, Full blood count, Intensive care, Metabolic function test, Pericardial effusion, Right ventricular dysfunction

SMQs:, Torsade de pointes/QT prolongation (broad), Cardiac failure (narrow), Anaphylactic reaction (broad), Systemic lupus erythematosus (broad), Arrhythmia related investigations, signs and symptoms (broad), Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (narrow), Acute central respiratory depression (broad), Pulmonary hypertension (narrow), Haemodynamic oedema, effusions and fluid overload (narrow), Cardiomyopathy (narrow), Respiratory failure (broad), Drug reaction with eosinophilia and systemic symptoms syndrome (broad), Noninfectious myocarditis/pericarditis (broad)

Life Threatening? No

Birth Defect? No

Died? Yes

Date died: 2022-08-15

Days after onset: 2

Permanent Disability? No

Recovered? No

Office Visit? No

ER Visit? No

ER or Doctor Visit? No

Hospitalized? No

Previous Vaccinations:

Total reported to date:

- 1400 AE, majority in children
- 65 serious and life-threatening events, 62 in children
- Lot was not recalled

Other Medications: acetylcysteine NEB, albuterol NEB, Epidiolex, Vitamin D, clobazam, clonidine, felbamate, furosemide, glycopyrrolate, Culturelle, Iorazepam, melatonin, methadone, Nano VM, omeprazole, pyllium, hypertonic saline 7% NEB

Current Illness: Initially admitted on 7/15 after a GT replacement w/ GI, transferred to PICU for respiratory failure requiring continued intubation in the setting of COVID-19 Pneumonia.

Preexisting Conditions: h/o neurometabolic/degenerative disorder, intractable seizures, GDD, GT dependence

Allergies: NKA

Diagnostic Lab Data: CBC, CMP, coag panel, respiratory cultures, Echocardiogram (08/13/22) demonstrates severely diminished LV function (LV EF=15%), moderately diminished RV function, and small posterior pericardial effusion. Aortic valve leaflets appear echogenic (possibly calcified) without stenosis or insufficiency.

CDC Split Type:

Write-up: Acute bradycardia and subsequent cardiac arrest on 8/13 leading to ICU transfer on epinephrine, milrinone, amiodarone, and fentanyl drips. Patient ultimately passed away on 8/15 after another cardiac arrest.

Documents Leaked from EMA

"Bait and Switch": Remove Manufacturers' Liability at the EU Level, while Promising Stronger Liability Protection to Public/Member States

Opinion of the European Regulators (EMA) Nov 30, 2020:

- Pfizer/BioNTech manufacturing processes (at all sites) were NOT GMP compliant:
 - Switch from Process 1 (clin trial) to Process 2 (commercial) only 250 subj in clinical trial received Process 2
 - Regulators deemed data non-comparable and wanted a new study
 - Not validated, proprietary "black box" process, much information missing
 - No plan/deadline for cGMP compliance
- 117 Major Objections and Concerns listed by the regulators:
 - For any normal product, even a fraction of this would have halted the approval
 - All objections would need to be resolved before authorization
- 2 weeks later the product is "authorized" and shipped worldwide...

Pfizer Supply Agreements with EU Forced Member States to Waive All Liability:



Purchasers must "indemnify, defend and hold harmless Pfizer ... from and against any and all suits, claims, actions, demands, losses, damages, liabilities, settlements, penalties, fines, costs and expenses ... arising out of, relating to, or resulting from the Vaccine."



Regulatory "approval" was a sham:

Neither the regulators, nor vaccinators, nor most pharma employees know what is in the vials.

They are just following orders... Whose orders??

SAFEANDEFFECTIVE

Warp Speed Was a Military Operation

The State of War:

"Public Health Emergency" declaration suspends the Constitution, consolidates all power in the Executive branch (HHS)

The Weapons:

EUA Countermeasures funded by US DOD under Defense Production and Other Transaction Authority


•


The Shield:

2005 PREP Act removes liability for "covered persons" using "covered countermeasures" on condition of following orders of "health" authorities = license to kill Countermeasures are "medicines" without regulatory consumer safeguards


 21 USC 360bbb-3(k): use of EUA-covered medical countermeasure (MCM) products, once designated as such by the Secretary of Health and Human Services "shall not be considered to constitute a clinical investigation."

 Deployed by HHS Secretary based on "may be effective" opinion. No evidence from clinical trials required.





Accelerating Development of Safe and Effective Vaccines



- Platform Technologies Multiple Candidates Large Scale Manufacturing in Parallel with Clinical Trials Large Phase III Trials
 - Violation of cGMP (CFR Title 21*)
 - Not possible to manufacture <u>safe</u> products before safety is properly tested
 - "Platforms" do not exempt each product from full safety testing requirements



UNCLASSIFIED Saving Lives. Protecting Americans.

*https://www.fda.gov/drugs/pharmaceutical-quality-resources/current-good-manufacturing-practice-cgmp-regulations

by KEI. Linked herein is a comprehensive list of all US government COVID-19-related contracts obtained by KEI via FOIA.

- Advanced Technology Internationa (ATI) Underlying contract to execute MCDC and COVID-19 contracts on behalf of the federal government.
- DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016.
- DoD-ATI Other Transaction Authority Agreement W15QKN1691002-P00085. April 8, 2016. (Version obtained November 30, 2020 from HHS FOIA Reading Room)
- Aerpio respiratory condition treatment.
- DOD-Aerpio Statement of Work W81XWH1590001.
- DOD-Aerpio Project Approval Letter W81XWH1590001. July 28, 2020.
- Altimmure therapeutic.
- DoD-Altimmune Project Approval Letter W81XWH159001. June 17, 2020.
- DoD-Altimmune Statement of Work W81XWH159001.
- DoD-Altimmune Revised Project Approval Letter (3) W81XWH159001. February 3, 2021.
- DoD-Itimmune Revised Project Approval Letter (2) W81XWH159001. December 15, 2020.
- America's Blood Center convalescent plasma.
 - HHS/ASPR/BARDA-America's Blood Center Contract 75A50120000094 (includes Mods 1-8). April 17, 2020.
- DOD-America's Blood Centers Contract W911QY2190006. October 30, 2020.
- ANP Technologies diagnostics.
 - DoD-ANP Technologies Contract W911QY20D0019 (includes Mods 1-3). May 29, 2020.
- DOD-ANP Technologies Supply Order W911QY20D0019 (includes Mods 1-3). June 2, 2020.
- DOD-MP Technologies Supply Order W911QY20P0141 (includes Mod 1). April 17, 2020.
- AstraZeneca vaccine.
 - HHS/ASPR/BARDA-AstraZeneca Advanced Agreement to Other Transaction Authority Agreement 75A501-20-C-00114. May 20, 2020.
- HHS/ASPR/BARDA-AstraZeneca Modification of OTA Agreement 75A501-20-C-00114 MODP00001. July 31, 2020.
- AstraZeneca vaccine.
 - Dop-AstraZeneca Other Transaction Authority Agreement W15QKN2191003. October 28, 2020.
- AstraZeneca prophylactic monoclonal antibody.
 - DOD-AstraZeneca Contract W911QY2190001 (includes Mods 1, 2, 3, and 5). October 9, 2020.
- AstraZereca therapeutic.
 - DoD-AstraZeneca Contract W911QY20C0119 (includes Mod 1). September 30, 2020.
 - DoD-AstraZeneca Contract W911QY20C0119 (includes Mod 1). September 30, 2020. (Version obtained by FOIA)
- Alantic Diving Supply no-contact thermometers.
 - Atlantic Diving Supply Contract W911QY18D0019. September 16, 2020.
- Beckman Coulter diagnostic-related.
 - HHS/ASPR/BARDA-Beckman Coulter Contract 75A50119C00078. September 30, 2019.
 - HHS/ASPR/BARDA-Beckman Coulter Contract 75A50119C00078-P00001. May 15, 2020.
 - HHS/ASPR/BARDA-Beckman Coulter Contract 75A50120C00189. September 28, 2020.
- Biofire Defense diagnostics.
 - DoD-Biofire Defense Supply Order W911QY13D0080 Contract W911QY20F0271. April 24, 2020.
 DoD-Biofire Defense Supply Order W911QY13D0080 Contract W911QY20F0171 (includes Mods 1-2). May 23, 2020.
 DOD-Biofire Defense Supply Order W911QY20F0196 and W911QY20F0165 Contract W911QY13D0080 (includes Mod 1 of W911QY20F0196). April 17, 2020.
- BCG Federal Corp COVID-19-related support services.

- All contracts from DOD via ATI "management company", not directly with government
- Robert Kadlec (ASPR Secretary under Trump) personally controlled \$\$\$ contracts.
- Kadlec lead "update" to PREP
 Act to fully shield pharmas from
 liability. Ex-lobbyist for
 Emergent Biosolutions, a
 defense manufacturer which got
 contract to made J&J and AZ
 covid vaccines.

Full list available at https://www.keionline.org/covid -contracts



Pfizer

Contract

DEPARTMENT OF THE ARMY U.S. ARMY CONTRACTING COMMAND – NEW JERSEY PICATINNY ARSENAL, NEW JERSEY 07806-5000

REPLY TO ATTENTION OF

21 July 2020

Army Contracting Command – New Jersey ACC-NJ, Building 9 Picatinny Arsenal, NJ 07806

SUBJECT: Technical Direction Letter for Medical CRBN Defense Consortium (MCDC), Request for Prototype Proposals (RPP) 20-11, Objective PRE-20-11 for "COVID-19 Pandemic – Large Scale Vaccine Manufacturing Demonstration" (Pfizer, Inc.)

REF: Prizer Request for Technical Direction Letter, RPP 20-11 under OTA W15QKN-16-9-1002 for Objective PRE-20-11, dated 20 July 2020

Advanced Technology International ATTN: (b) (6), Sr. Contracts Manager 315 Sigma Drive Summerville, SC 29486



The Army Contracting Command – New Jersey (ACC-NJ), in supporting the Joint Project Manager – Medical Countermeasure Systems (JPM-MCS), issued MCDC RPP 20-11 on 09 June 2020. Members of the MCDC submitted proposals in accordance with this RPP. The Government received and evaluated all proposal(s) submitted and a Basis of Selection has been executed, selecting Pfizer, Inc. as the awardee. The Government requests that a Firm-Fixed-Price Project Agreement be issued to Pfizer, Inc. to award this proposal under Other Transaction Agreement W15QKN-16-9-1002, to be performed in accordance with the attached Government Statement of Work (SOW).

Based upon the acceptable update of Pfizer, Inc.'s proposal for "COVID-19 Pandemic – Large Scale Vaccine Manufacturing Demonstration" and 1) The Project Agreement Recipient's concurrence with the requirements included in the Government SOW; 2) An acceptable milestone schedule that meets SOW requirements, and; 3) The price proposed that has been analyzed by the Government, you are hereby directed to issue a Project Agreement to Pfizer, Inc. for the subject project. The total project value has been determined fair and reasonable and Pfizer, Inc.'s proposal has been selected IAW the above referenced Basis of Selection.

- Invoked by defense in the Motion to Dismiss Brook Jackson's case (Apr 2022)
- Judge agreed and dismissed the case (Mar 2023)
- Case being appealed

"Vaccine Development and Approval" was a performance art to fool the public

- Ordered "demonstration" (i.e. fake) in DOD contracts for vaccines
- Clinical trials were not ordered by DOD/HHS not possible for countermeasures
- cGMP compliance was mentioned in contracts but not possible to enforce due to PREP Act
- "Legally" there were no clinical trial subjects or investigators, and no informed consent – not possible for EUA countermeasures under PHE

A "medical product" for which there is no liability, all risk is forced onto recipients and all profits are privatized is not a medical product at all.